Edition:
India

Intersect ENT Inc (XENT.OQ)

XENT.OQ on NASDAQ Stock Exchange Global Market

32.10USD
15 Dec 2017
Change (% chg)

$0.25 (+0.78%)
Prev Close
$31.85
Open
$31.90
Day's High
$32.45
Day's Low
$31.70
Volume
123,023
Avg. Vol
58,841
52-wk High
$34.40
52-wk Low
$11.00

Latest Key Developments (Source: Significant Developments)

‍James Flynn​ reports 5.92 pct passive stake in Intersect ENT
Friday, 17 Nov 2017 

Nov 16 (Reuters) - Intersect Ent Inc ::‍James Flynn​ reports 5.92 percent passive stake in Intersect ENT as of Nov 6 - SEC filing.  Full Article

FDA performs pre-approval inspection of Intersect ENT's menlo park facility
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Intersect ENT Inc :FDA performs pre-approval inspection of Intersect ENT's menlo park facility.Intersect ENT Inc - ‍FDA has set a pdufa target action date of January 7, 2018​.Intersect ENT Inc - ‍at conclusion of inspection, FDA issued a form 483 with four inspectional observations​.Intersect ENT Inc - does not expect inspectional observations to impact timeline for a decision from FDA on approval of sinuva implant​.  Full Article

Intersect ENT Inc reports Q3 revenue $22.3 million
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Intersect ENT Inc :Intersect ENT Inc reports third quarter 2017 results.Q3 revenue $22.3 million versus I/B/E/S view $21.5 million.Sees q4 2017 revenue $27.3 million to $27.8 million.Intersect ENT Inc - ‍outlook for 2017 gross margin continues to be about 84%​.Intersect ENT Inc - ‍for full year 2017 expects revenue in range of $94.1-$94.6 million​.  Full Article

Intersect Q2 loss per share $0.21
Wednesday, 3 Aug 2016 

Intersect ENT Inc : Q2 loss per share $0.21 . Q2 revenue $19.3 million versus I/B/E/S view $18.8 million . Intersect ENT reports second quarter 2016 results . Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S . Sees Q3 2016 revenue about $17.8 million . Fy2016 revenue view $78.3 million, q3 revenue view $18.4 million -- Thomson Reuters I/B/E/S .Expects full year revenue at low end of previous guidance range of $78 million-$80 million.  Full Article

Intersect ENT announces FDA submission of NOVA
Monday, 1 Aug 2016 

Intersect ENT Inc :Intersect ENT announces FDA submission of NOVA bioabsorbable steroid releasing implant for patients with chronic sinus disease.  Full Article

BRIEF-Intersect ENT prelim Q2 revenue $19.3 mln
Monday, 18 Jul 2016 

Corrects third bullet to preliminary revenue, not reported revenue.Intersect Ent Inc : Says company's Chief Commercial Officer Chas McKhann is departing for personal reasons . Announces preliminary Q2 revenue and business update .Q2 preliminary revenue $19.3 million versus I/B/E/S view$18.8 million.  Full Article

Intersect ENT Inc reaffirms FY 2016 revenue guidance
Friday, 6 May 2016 

Intersect ENT Inc:Continues to project revenue for FY 2016 in the range of $78-$80 million.  Full Article

Intersect ENT Inc gives Q4, FY 2015 revenue guidance; gives FY 2016 revenue guidance
Tuesday, 12 Jan 2016 

Intersect ENT Inc:Anticipates revenue for the Q4 2015 in the range of $18.6 to $18.8 million.Anticipates revenue for the FY 2015 of approximately $61.4 to $61.6 million.Continues to expect significant revenue growth in FY 2016 and forecasts revenue to be between $78 and $80 million.  Full Article

BRIEF-‍James Flynn​ reports 5.92 pct passive stake in Intersect ENT

* ‍James Flynn​ reports 5.92 percent passive stake in Intersect ENT as of Nov 6 - SEC filing Source text : (http://bit.ly/2jwmJXW) Further company coverage: